RT Conference Proceedings
T1 Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups
A1 Choy, J.
A1 Suarez Rodriguez, C.
A1 Larkin, J.
A1 Patel, P.
A1 Perez Valderrama, B.
A1 Rodriguez-Vida, A.
A1 Glen, H.
A1 Thistlethwaite, F.
A1 Ralph, C.
A1 Srinivasan, G.
A1 Mendez Vidal, M. J.
A1 Carter, A.
A1 Tyson, C.
A1 Prendergast, A.
A1 Mousa, K.
A1 Powles, T. B.
A1 Szabados, B. E.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-12-01
LK https://hdl.handle.net/10668/27421
UL https://hdl.handle.net/10668/27421
LA en
DS RISalud
RD Apr 17, 2025